Growth factorInjectable

CJC-1295

Also known as: Modified GRF (1–29)

CJC-1295 is a synthetic peptide based on growth-hormone-releasing hormone (GHRH), studied for how the body's own growth-hormone axis is signalled.

Physician-reviewedDr. Bushra Mir, Medical Director · DHA-licensedReviewed 10 July 2026

The molecule, up close

Class: GHRH analogue (secretagogue)
Origin: Based on growth-hormone-releasing hormone
Chemistry: Modified GRF (1–29) peptide
Typical format: Injectable
Regulatory status: Prescription-only; not permitted in competitive sport

This page is educational information, not medical advice or an offer of treatment. Peptides used clinically are prescription medicines; whether any is appropriate for you is a decision a physician makes after a diagnostic assessment.

What it is

CJC-1295 belongs to a group of peptides called growth-hormone secretagogues — compounds studied for their effect on the body's own growth-hormone signalling rather than for replacing the hormone directly. It's based on GHRH, the natural signal that tells the pituitary to release growth hormone.

The appeal in research terms is the idea of working with the body's own rhythm; the reality is that it's still under study, prescription-only, and carefully controlled.

What it's studied for

Interest centres on growth-hormone-axis signalling and, in research contexts, recovery and body composition. It's often discussed alongside other secretagogues.

These are areas of study, and it shouldn't be equated with approved growth-hormone therapy or presented as a performance product.

The science

CJC-1295 mimics GHRH, prompting the pituitary gland to release growth hormone in the body's own pulsatile pattern rather than delivering the hormone directly. Modifications are designed to extend how long it stays active.

The growth-hormone axis affects many systems, so its signalling is complex and its clinical effects aren't yet established.

Typical form

Injectable

Shown in the dispensing format most often used in research and clinical settings. Where any protocol is appropriate, the route, dose and schedule are a physician’s decision — not a fixed recipe.

Safety & considerations

Prescription-only and physician-supervised. Because the growth-hormone axis affects many systems, assessment, dosing and monitoring are strictly medical.

It's prohibited in competitive sport, and product sourcing is a genuine safety concern with any research peptide.

Status & oversight

CJC-1295 is a research compound used under physician supervision, and is prohibited under anti-doping rules. Any use is individualised and physician-led.

Common questions

CJC-1295, in brief.

What is CJC-1295 used for?

It's studied for growth-hormone-axis signalling and, in research, recovery and body composition. It's still under study and prescription-only rather than an approved therapy.

Is CJC-1295 the same as growth hormone?

No. It's studied as a signal that prompts the body's own growth-hormone release, rather than being growth hormone itself, and it isn't a substitute for approved growth-hormone treatment.

Is CJC-1295 banned in sport?

Yes. Growth-hormone secretagogues are prohibited under World Anti-Doping Agency rules, so competitive athletes should not use it.

Peptides of this kind are prescription medicines. Whether any protocol is appropriate is decided the way the rest of the practice works — from data, after an assessment.

How our longevity assessment works Back to the peptide field guide

How this is written

Physician-reviewed and evidence-led. We describe what a compound is studied for and where the evidence stands — not what it will do for you — and we revise pages as the science changes. Reviewed by Dr. Bushra Mir, Medical Director · DHA-licensed.

References

Peer-reviewed references for this compound are added by the physician author before publication.